Business Wire·Oct 28, 2026, 8:30 AM ET

Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

VIR

Vir Biotechnology appointed Suzanne Topalian, M.D., to its Board of Directors effective October 27, 2026.
Dr. Topalian serves as the Bloomberg-Kimmel Professor of Cancer Immunotherapy at Johns Hopkins University School of Medicine.
She currently acts as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director of the Melanoma/Skin Cancer Program at the Kimmel Cancer Center.
CEO Marianne De Backer stated Dr. Topalian's expertise will support the company's oncology portfolio & PRO-XTEN platform development.
Dr. Topalian expressed excitement to contribute to Vir's progress in developing masked T-cell engagers for solid tumors.
Her research on anti-tumor immunity & PD-1 blockade helped establish immune checkpoint inhibition as a core oncology pillar.
She has authored over 180 peer-reviewed publications & is recognized as one of the most highly cited biomedical researchers.
Dr. Topalian was elected to the National Academy of Medicine in 2017 & the AACR Academy in 2022.
She holds a B.A. from Wellesley College, an M.D. from Tufts University, & completed postgraduate training at Thomas Jefferson University Hospital & the NIH.
Vir Biotechnology is a clinical-stage company developing treatments for infectious diseases & cancer using its PRO-XTEN platform.
The company holds exclusive rights to the PRO-XTEN masking platform for oncology & infectious disease applications.
A disclaimer notes Dr. Topalian's directorship does not constitute an endorsement by Johns Hopkins University.